Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Khlong Luang, Pathumthani, Thailand.
Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Semin Hematol. 2019 Jul;56(3):194-200. doi: 10.1053/j.seminhematol.2018.08.003. Epub 2018 Aug 24.
Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian population and mixed race individuals, extending allogeneic stem cell transplant for almost all patients in need. As many multiple potential related donors may now be available, it is increasingly clear that not all of these donors can provide equivalent transplant outcomes. Here we review the current available evidence of donor characteristics known to be associated with transplant outcomes for different types of haploidentical transplants using unmanipulated grafts (with post-transplant cyclophosphamide-based graft-vs-host prophylaxis and G-CSF and anti-thymocyte globulin approach) as well as modified grafts (with either selective or complete T-cell depletion). While various platforms use haploidentical donors, graft manipulation and approach to prevent graft-vs-host post-transplant may impact on donor selection and transplant outcomes.
近年来,单倍体干细胞移植的进展使得 HLA 半匹配相关供者可用于异基因干细胞移植,并有助于克服移植中最重要的限制之一,即供者的可用性,特别是对于非白种人群和混血个体,将异基因干细胞移植扩展到几乎所有有需要的患者。由于现在可能有许多潜在的相关供者,越来越明显的是,并非所有这些供者都能提供同等的移植结果。在这里,我们回顾了目前可用的关于与不同类型单倍体异体移植的移植结果相关的供者特征的证据,这些移植使用未处理的移植物(基于移植后环磷酰胺的移植物抗宿主病预防和 G-CSF 加抗胸腺细胞球蛋白方法)和修饰的移植物(选择性或完全 T 细胞耗竭)。虽然各种平台都使用单倍体供者,但移植物处理和预防移植后移植物抗宿主病的方法可能会影响供者选择和移植结果。